Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

PHR1526

Supelco

Dexaméthasone

Pharmaceutical Secondary Standard; Certified Reference Material

Synonyme(s) :

(11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-méthylpregna-1,4-diène-3,20-dione, 9α-Fluoro-16α-méthyl-11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione, 9α-Fluoro-16α-méthylprednisolone, Prednisolone F

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H29FO5
Numéro CAS:
Poids moléculaire :
392.46
Numéro Beilstein :
2066651
Numéro CE :
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Source biologique

synthetic

Niveau de qualité

Qualité

certified reference material
pharmaceutical secondary standard

Agence

BP
EP
USP
traceable to BP 578
traceable to Ph. Eur. D0700000
traceable to USP 1176007

Pression de vapeur

<0.0000001 kPa ( 25 °C)

Famille d'API

dexamethasone

CofA (certificat d'analyse)

current certificate can be downloaded

Conditionnement

pkg of 1 g

Conditions de stockage

protect from light

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Couleur

white

Pf

262-264 °C (lit.)

Solubilité

DMSO: soluble
acetone: sparingly soluble
chloroform: slightly soluble
dioxane: soluble
ethanol: sparingly soluble
ether: very slightly soluble
methanol: sparingly soluble
water: practically insoluble

Application(s)

pharmaceutical (small molecule)

Format

neat

Conditions d'expédition

ambient

Température de stockage

2-30°C

Chaîne SMILES 

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

Clé InChI

UREBDLICKHMUKA-CXSFZGCWSA-N

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Dexamethasone is a corticosteroid medication, with anti-inflammatory activity. It is widely used for inflammatory ocular conditions and for the treatment of skin-allergic reactions.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

Dexamethasone may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using voltammentric techniques and reversed-phase high-performance liquid chromatography technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Actions biochimiques/physiologiques

Agent anti-inflammatoire du type glucocorticoïde. Régule la survie, la croissance et la différenciation des lymphocytes T. Inhibe l′induction de l′oxyde nitrique synthase.

Remarque sur l'analyse

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Autres remarques

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Note de bas de page

To see an example of a Certificate of Analysis for this material enter LRAC2894 in the slot below. This is an example certificate only and may not be the lot that you receive.

Produits recommandés

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Simultaneous determination of dexamethasone and moxifloxacin in pharmaceutical formulations using stability indicating HPLC method
Razzaq NS, et al.
Arabian Journal of Chemistry, 10(3), 321-328 (2017)
Determination of prednisolone, dexamethasone and hydrocortisone in pharmaceutical formulations and biological fluid samples by voltammetric techniques using b-cyclodextrin modified carbon paste electrode
Balaji K, et al.
African Journal of Pharmacy and Pharmacology, 2(8), 157-166 (2008)
S Choi et al.
British journal of anaesthesia, 112(3), 427-439 (2014-01-15)
Brachial plexus nerve blocks (BPBs) have analgesic and opioid sparing benefits for upper extremity surgery. Single-injection techniques are limited by the pharmacological duration and therapeutic index of local anaesthetics (LAs). Continuous catheter techniques, while effective can present management challenges. Off-label
Sara Bringhen et al.
Blood, 124(1), 63-69 (2014-05-24)
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who
A Keith Stewart et al.
The New England journal of medicine, 372(2), 142-152 (2014-12-09)
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. We randomly assigned 792

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique